The role of the gut microbiome in Alzheimer's disease
DOI:
https://doi.org/10.56782/pps.273Keywords:
gut microbiome, Alzheimer's, brain-gut axis, neurogenesisAbstract
Introduction: Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive loss of memory and cognitive function. Although the etiopathogenesis of this condition is not yet fully understood, in recent years there has been a growing body of research indicating an important link between the gut microbiome and brain health, including its involvement in the pathogenesis of AD. Aim of the article: The purpose of this article is to outline the role of the gut microbiome in the development and progression of AD, and to discuss potential therapeutic strategies resulting from a better understanding of this relationship. State of the Art: The gut microbiome, consisting of trillions of microorganisms, plays a key role in regulating immune response and neurological function through the gut-brain axis. Microbial imbalances in the gut, known as dysbiosis, can lead to chronic inflammation and increased intestinal permeability. Such conditions promote neuroinflammation, which is an important factor in the pathogenesis of AD. In addition, gut bacteria affect the production of metabolites, such as short-chain fatty acids (SCFAs), which exhibit neuroprotective properties. Conclusions: Understanding the role of the gut microbiome in Alzheimer's disease opens up new therapeutic possibilities. Probiotics, prebiotics and dietary interventions can help restore microbial balance, reduce inflammation and improve brain health. Research on the gut microbiome may provide key information to develop innovative strategies for AD prevention and treatment.
Downloads
References
1. Tiwari, S.; Atluri, V.; Kaushik, A.; Yndart, A.; Nair, M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomed. 2019, 14, 5541-5554. DOI: 10.2147/IJN.S200490 DOI: https://doi.org/10.2147/IJN.S200490
2. Practical Medicine. Available online: https://www.mp.pl/pacjent/neurologia/choroby/151134,choroba-alzheimera. (accessed on 25.05.2024).
3. NEUROEXPERT Encyclopedia of Neurophysiology. Available online: https://neuroexpert.org/mikrobiota-jelit-a-choroba-alzheimera/ (accessed on 25.05.2024).
4. Grabrucker, S.; Marizzoni, M.; Silajdžić, E.; Lopizzo, N.; et al. Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis. Brain 2023, 146, 4916-4934. DOI: 10.1093/brain/awad303 DOI: https://doi.org/10.1093/brain/awad303
5. Angelucci, F.; Cechowa, K.; Amlerowa, J.; Horta, J. Antibiotics, gut microbiota, and Alzheimer’s disease. J. Neuroinflamm. 2019, 16, Art. No: 108. DOI: 10.1186/s12974-019-1494-4 DOI: https://doi.org/10.1186/s12974-019-1494-4
6. Scheltens, P.; Strooper, B.D.; Kivipelto, M.; Holstege, H.; et al. Alzheimer’s disease. Lancet. 2021, 397, 1577–1590. DOI: 10.1016/S0140-6736(20)32205-4 DOI: https://doi.org/10.1016/S0140-6736(20)32205-4
7. Leszek, J. Alzheimer’s disease: current knowledge, therapeutic perspectives. Pol. Neurol. Rev. 2012, 8, 101-106.
8. Huttenhower, C.; Gevers, D.; Knight, R.; Abubucker, S.; Badger, J.H.; et al. Structure, Function and Diversity of the Healthy Human Microbiome. Nature. 2012, 486, 207–214. DOI: 10.1038/nature11234 DOI: https://doi.org/10.1038/nature11234
9. Askarova S.; Umbayev, B.; Masoud, A. R.; Kaiyrlykyzy, A.; et al. The Links Between the Gut Microbiome, Aging, Modern Lifestyle and Alzheimer's Disease. Front. Cell. Infec. Microbiol. 2020, 10, Art. No: 104. DOI: 10.3389/fcimb.2020.00104 DOI: https://doi.org/10.3389/fcimb.2020.00104
10. Rutayisire, E.; Huang, K.; Liu, Y.; et al. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants’ life: a systematic review. BMC Gastroenterol. 2016, 16, Art. No: 86. DOI: 10.1186/s12876-016-0498-0 DOI: https://doi.org/10.1186/s12876-016-0498-0
11. Oziom, J.; Budrewicz, S. The role of intestinal microbiota in the pathogenesis and course of selected diseases of the nervous system. Pol. Neurol. Rev. 2019, 15(1), 1–11. DOI: 10.5603/PPN.2019.0005 DOI: https://doi.org/10.5603/PPN.2019.0005
12. Barrett, E.; Ross, R.P.; O’Toole, P.W.; et al. γ-Aminobutyric acid production by culturable bacteria from the human intestine. J. Appl. Microbiol. 2012, 113, 411–417. DOI: 10.1111/j.1365-2672.2012.05344.x DOI: https://doi.org/10.1111/j.1365-2672.2012.05344.x
13. Vogt, N.M.; Kerby, R.L.; Dill-McFarland, K.A.; et al. Gut microbiome alterations in Alzheimer’s disease. Sci. Rep. 2017, 7, Art. No. 13537. DOI: 10.1038/s41598-017-13601-y DOI: https://doi.org/10.1038/s41598-017-13601-y
14. Murray, E.R.; Kemp, M.; Nguyen, T.T. The Microbiota-Gut-Brain Axis in Alzheimer’s Disease: A Review of Taxonomic Alterations and Potential Avenues for Interventions. Arch. Clin. Neuropsychol. 2022, 37, 595–607. DOI: 10.1093/arclin/acac008 DOI: https://doi.org/10.1093/arclin/acac008
15. Ghosh, T.S.; Shanahan, F.; O'Toole, P.W. The gut microbiome as a modulator of healthy ageing. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 565-584. DOI: 10.1038/s41575-022-00605-x DOI: https://doi.org/10.1038/s41575-022-00605-x
16. Cryan, J.F.; O'Riordan, K.J.; Cowan, C.S.M.; et al. The Microbiota-Gut-Brain Axis. Physiol. Rev. 2019, 99, 1877-2013. DOI: 10.1152/physrev.00018.2018 DOI: https://doi.org/10.1152/physrev.00018.2018
17. Bonaz, B.; Bazin, T.; Pellissier, S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front. Neurosci. 2018, 12, Art. No. 49 . DOI: 10.3389/fnins.2018.00049 DOI: https://doi.org/10.3389/fnins.2018.00049
18. Dinan, T.G.; Cryan, J.F. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol. Clin. North. Am. 2017, 46, 77–89. DOI: 10.1016/j.gtc.2016.09.007 DOI: https://doi.org/10.1016/j.gtc.2016.09.007
19. Galland, L. The gut microbiome and the brain. J. Med. Food. 2014, 17, 1261–1272. DOI: 10.1089/jmf.2014.7000 DOI: https://doi.org/10.1089/jmf.2014.7000
20. Alam, R.; Abdolmaleky, H.M.; Zhou, J.R. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2017, 174, 651–660. DOI: 10.1002/ajmg.b.32567 DOI: https://doi.org/10.1002/ajmg.b.32567
21. De Lucia, C.; Murphy, T.; Maruszak, A.; et al. Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells. Aging Dis. 2021, 12, 2151-2172. DOI: 10.14336/AD.2021.0409 DOI: https://doi.org/10.14336/AD.2021.0409
22. Kim, T.A.; Syty, M.D.; Wu, K.; Ge, S. Adult hippocampal neurogenesis and its impairment in Alzheimer's disease. Zool. Res. 2022, 43, 481-496. DOI: 10.24272/j.issn.2095-8137.2021.479 DOI: https://doi.org/10.24272/j.issn.2095-8137.2021.479
23. Wu, G.D.; Chen, J.; Hoffmann, C.; et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011, 334, 105–108. DOI: 10.1126/science.1208344 DOI: https://doi.org/10.1126/science.1208344
24. McGrattan, A.M.; McGuinness, B.; McKinley, M.C.; et al. Diet and Inflammation in Cognitive Ageing and Alzheimer’s Disease. Curr. Nutr. Rep. 2019, 8, 53–65. DOI: 10.1007/s13668-019-0271-4 DOI: https://doi.org/10.1007/s13668-019-0271-4
25. Davis, C.; Bryan, J.; Hodgson, J.; Murphy, K. Definition of the Mediterranean Diet; a Literature Review. Nutrients. 2015, 7, 9139–9153. DOI: 10.3390/nu7115459 DOI: https://doi.org/10.3390/nu7115459
26. Institute of Microecology. Available online: https://instytut-mikroekologii.pl/dieta-i-mikrobiota-a-choroba-alzheimera/ (accessed 01.06.2024).
27. Mosconi, L.; Murray, J.; Tsui, W. H.; Li, Y.; et al. Mediterranean diet and magnetic resonance imaging-assessed brain atrophy in cognitively Normal individuals at risk for Alzheimer's disease. J. Prev. Alzheimers Dis. 2014, 1, 23-32. DOI: https://doi.org/10.14283/jpad.2014.17
28. Flanagan, E.; Müller. M.; Hornberger, M.; Vauzour, D. Impact of Flavonoids on Cellular and Molecular Mechanisms Underlying Age-Related Cognitive Decline and Neurodegeneration. Curr. Nutr. Rep. 2018, 7, 49-57. DOI: 10.1007/s13668-018-0226-1 DOI: https://doi.org/10.1007/s13668-018-0226-1
29. Devassy, J.G.; Leng, S.; Gabbs, M.; et al. Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease. Adv. Nutr. 2016, 7, 905–916. DOI: 10.3945/an.116.012187 DOI: https://doi.org/10.3945/an.116.012187
30. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015, 11, 1007-1014. DOI: 10.1016/j.jalz.2014.11.009 DOI: https://doi.org/10.1016/j.jalz.2014.11.009
31. Minter, M.R.; Zhang, C.; Leone, V.; Ringus, D.L.; Zhang, X.; et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci. Rep. 2016, 6, Art. No. 30028. DOI: 10.1038/srep30028 DOI: https://doi.org/10.1038/srep30028
32. Kountouras, J.; Boziki, M.; Gavalas, E.; Zavos, C.; Grigoriadis, N.; Deretzi, G, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J. Neurol. 2009, 256, 758-67. DOI: 10.1007/s00415-009-5011-z DOI: https://doi.org/10.1007/s00415-009-5011-z
33. Janicka, N.; Świątek, M.; Kaczmarek-Zalewska, A.; Kotarba, M.; Karolczyk, P.; Jońca, B.; Karłowicz-Bodalska, K. Obiecujące zastosowania bakterii probiotycznych jako wsparcie terapii depresji, chorób neurodegeneracyjnych – przegląd najnowszych badań. [Promising uses of probiotic bacteria as support for therapy of depression, neurodegenerative diseases - review of recent studies] Farm. Pol. 2023, 79, Art. No: 2. DOI: 10.32383/farmpol/168696 DOI: https://doi.org/10.32383/farmpol/168696
34. Akbari, E.; Asemi, Z.; Daneshvar Kakhaki, R.; Bahmani, F.; Kouchaki, E.; Tamtaji, O. R.; Hamidi, G. A. and Salami, M. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Front. Aging Neurosci. 2016, 8, Art. No: 256. DOI: 10.3389/fnagi.2016.00256. DOI: https://doi.org/10.3389/fnagi.2016.00256
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Katarzyna Łysiak, Anna Łysiak
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
